NFE2L2 and pulmonary fibrosis: Our results suggest that protodioscin is of therapeutical potential for treating pulmonary fibrosis, and, in this context, we suggest that the NBR1-p62-Nrf2 pathway represents a promising therapeutic target that can be further explored.